Multiple myeloma Trials in Montvale, United States
Conditions / Multiple myeloma / Montvale, United States
Clinical trials for Multiple myeloma investigate a range of treatment strategies and patient populations.
37 total trials for this combination
Showing top 10 of 37 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06215118 | A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | RECRUITING | — |
| NCT05462639 | Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma | NO_LONGER_AVAILABLE | — |
| NCT06179888 | Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma | RECRUITING | — |
| NCT05014412 | A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment | COMPLETED | PHASE2 |
| NCT06083922 | A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) | RECRUITING | — |
| NCT05775094 | A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT03530683 | A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma | TERMINATED | PHASE1 |
| NCT03269136 | PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma | COMPLETED | PHASE1 |
| NCT04478123 | Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer | COMPLETED | PHASE2 |
| NCT05020236 | A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments | RECRUITING | PHASE3 |